


Please type a plus sign (+) inside this box → +



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/817,622
Filing Date	April 2, 2004
First Named Inventor	Garlich et al.
Group Art Unit	1814 1626 1618
Examiner Name	Unassigned Stockton Jones
Attorney Docket Number	224297

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
[Signature]	BO	6,165,440		Esenaliev	Dec. 26, 2000	
	BP	6,436,386	B1	Roberts et al.	Aug. 20, 2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
[Signature]	BQ	WO	94/00145	A1	THE DOW CHEMICAL COMPANY	Jan. 6, 1994		
	BR	WO	96/20698	A2	THE BOARD OF REGENTS THE UNIVERSITY OF MICHIGAN	Jul. 11, 1996		
[Signature]	BS	WO	00/66090	A1	BIOTECH AUSTRALIA PTY LTD.	Nov. 9, 2000		
	BT	WO	02/04409	A2	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Jan. 17, 2002		
[Signature]	BU	WO	02/40058	A2	SHEARWATER CORP.	May 23, 2002		
	BV	WO	03/087389	A2	GENESEGUES, INC.	Oct. 23, 2003		
	BW	WO	03/088950	A1	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	Oct. 30, 2003		
[Signature]	BX	WO	2004/089345	A1	SEMAFORE PHARMACEUTICALS INC.	Oct. 21, 2004		
	BY	WO	2004/089356	A2	SEMAFORE PHARMACEUTICALS INC.	Oct. 21, 2004		
[Signature]	BZ	EP	0 524 055	A1	SYNTHELABO	Jan. 20, 1993		X*
	CA	EP	0 568 096	A1	HODOGAYA CHEMICAL CO., LTD.	Nov. 3, 1993		

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
[Signature]	CB	Foster et al., <i>Science</i> , 286, 2507-2510 (1999)		
	CC	Hans et al., <i>Current Opinion in Solid State and Materials Science</i> , 6, 319-327 (2002)		
[Signature]	CD	Hood et al., <i>Science</i> , 296, 2404-2407 (2002)		
	CE	Kreuter, <i>European J. of Drug Metabolism and Pharmacokinetics</i> , 3, 253-256 (1994)		
[Signature]	CF	Oh et al., <i>J. of Controlled Release</i> , 57, 269-280 (1999)		
	CG	Otsuka et al., <i>Advanced Drug Delivery Reviews</i> , 55, 403-419 (2003)		
[Signature]	CH	Panyam et al., <i>Advanced Drug Delivery Reviews</i> , 55, 329-347 (2003)		
	CI	Sahoo et al., <i>DDT</i> , 8, 1112-1120 (2003)		

Examiner Signature		Date Considered	9/29/04
--------------------	--	-----------------	---------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/817,622
Filing Date	April 2, 2004
First Named Inventor	Garlich et al.
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	224297

Sheet	1	of	1
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No ⁺⁺

[Handwritten signature]

9/29/86

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → +

April 2, 2004

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
Sheet	1	of	2	Application Number	Unassigned 10/817,622
				Filing Date	April 2, 2004
				First Named Inventor	Garlich et al.
				Group Art Unit	Unassigned 7626 1618
				Examiner Name	Unassigned Stockton Jones
				Attorney Docket Number	224297

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	AA	6,593,353	B1	Gudkov et al.	July 15, 2003	
	AB	2002/0019425	A1	Gudkov et al.	Feb. 2, 2002	
	AC	2002/0150954	A1	Durden	Oct. 17, 2002	
	AD	2003/0073611	A1	Gudkov et al.	April 17, 2003	
	AE	2003/0144331	A1	Gudkov et al.	July 31, 2003	
	AF	2003/0176318	A1	Gudkov et al.	Sept. 18, 2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	AG	WO	98/35703	A2	THE SALK INSTITUTE FOR BIOLOGICAL STUDIES	Aug. 20, 1998		
	AH	WO	99/41985	A1	QUARK BIOTECH, INC.	Aug. 26, 1999		
	AI	WO	00/44364	A2	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS	Aug. 3, 2000		

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No**	
A	AJ	Adzamli et al., <i>J. Med. Chem.</i> , 32, 139-144 (1989)			
	AK	Bassi et al., <i>Mutation Research</i> , 499, 163-176 (2002)			
	AL	Birnbaum et al., <i>J. Nanoparticle Research</i> , 2, 173-181 (2000)			
	AM	Botchkarev et al., <i>American J. of Path.</i> , 158, 1913-1919 (2001)			
	AN	Botchkarev et al., <i>Cancer Research</i> , 60, 5002-5006 (2000)			
	AO	Choi et al., <i>J. of Dispersion Science and Tech.</i> , 24, 475-487 (2003)			
	AP	Chu et al., <i>Bioconjugate Chem.</i> , 8, 103-105 (1997)			
	AQ	Duan et al., <i>Annals of Neurology</i> , 52, 597-606 (2002)			
	AR	Fujisaki et al., <i>J. of Drug Targeting</i> , 4, 117-123 (1996)			
	AS	Hirabayashi et al., <i>BioPharmaceutics & Drug Disposition</i> , 23, 307-315 (2002)			
	AT	Hirabayashi et al., <i>Clin. Pharmacokinetics</i> , 42, 1319-1330 (2003)			
	AU	Hirabayashi et al., <i>J. of Controlled Release</i> , 70, 183-191 (2001)			
	AV	Hosain et al., <i>J. Nucl. Med.</i> , 37, 105-107 (1996)			
	AW	Kasugai et al., <i>J. of Bone and Mineral Research (Suppl 1)</i> , 14, S534 (1999)			
	AX	Kasugai et al., <i>J. of Bone and Mineral Research</i> , 15, 936-943 (2000)			
V	AY	Kelly et al., <i>J. of the American Society of Nephrology</i> , 14, 128-138 (2003)			
	AZ	Kingman, <i>DDT</i> , 5, 7-8 (2000)			
	BA	Komarov et al., <i>Science</i> , 285, 1733-1737 (1999)			
	BB	Komarova et al., <i>Biochem. Pharm.</i> , 62, 657-667 (2001)			
B	BC	Komarova et al., <i>J. Bio. Chem.</i> , 278, 15465-15468 (2003)			
	BD	Li et al., <i>J. of Controlled Release</i> , 68, 41-52 (2000)			

Examiner Signature		Date Considered	9/29/04
--------------------	--	-----------------	---------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

2

of

2

Application Number

Unassigned

10/8/7, 620

Filing Date

April 2, 2004

First Named Inventor

Garlich et al.

Group Art Unit

Unassigned

1618

Examiner Name

Unassigned

love

Attorney Docket Number

224297

Examiner
Initials _____

Doc.
No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.

Translation

Yes

No. 4

8 E

Lin et al., *DNA Repair*, 2, 1-11 (2003)

BF

Mocanu et al., *FEBS Letters*, 555, 302-306 (2003)

B G

Shakespeare et al., *PNAS*, 97, 9373-9378 (2000)

BH

Sturtz et al., *Eur. J. Med. Chem.*, 27, 825-833 (1992)

BI

Sturtz et al., *Eur. J. Med. Chem.*, 28, 899-903 (1993)

BJ

Wang et al., *Bioconjugate Chem.*, 14, 853-859 (2003)

BK

Wingen et al., *J. Cancer Res. Clin. Oncol.*, 111, 209-219 (1986)

BL

Zhu et al., *J. of Medicinal Chem.*, 45, 5090-5097 (2002)

Examiner Signature

Date Considered

9/29/01

- * An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).